TY - JOUR
KW - Analgesics, Opioid/therapeutic use
KW - Buprenorphine/therapeutic use
KW - Female
KW - Humans
KW - Infant, Newborn
KW - Methadone/therapeutic use
KW - Neonatal Abstinence Syndrome/diagnosis/therapy
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/diagnosis/drug therapy/physiopathology
KW - Pregnancy
KW - Pregnancy Complications/diagnosis/drug therapy/physiopathology
KW - Pregnancy Outcome
AU - ACOG Committee on Health Care for Underserved Women
AU - American Society of Addiction Medicine
A1 - 
AB - Opioid use in pregnancy is not uncommon, and the use of illicit opioids during pregnancy is associated with an increased risk of adverse outcomes. The current standard of care for pregnant women with opioid dependence is referral for opioid-assisted therapy with methadone, but emerging evidence suggests that buprenorphine also should be considered. Medically supervised tapered doses of opioids during pregnancy often result in relapse to former use. Abrupt discontinuation of opioids in an opioid-dependent pregnant woman can result in preterm labor, fetal distress, or fetal demise. During the intrapartum and postpartum period, special considerations are needed for women who are opioid dependent to ensure appropriate pain management, to prevent postpartum relapse and a risk of overdose, and to ensure adequate contraception to prevent unintended pregnancies. Patient stabilization with opioid-assisted therapy is compatible with breastfeeding. Neonatal abstinence syndrome is an expected and treatable condition that follows prenatal exposure to opioid agonists.
BT - Obstetrics and gynecology
C5 - Opioids & Substance Use
CP - 5
CY - United States
DO - 10.1097/AOG.0b013e318256496e
IS - 5
JF - Obstetrics and gynecology
N2 - Opioid use in pregnancy is not uncommon, and the use of illicit opioids during pregnancy is associated with an increased risk of adverse outcomes. The current standard of care for pregnant women with opioid dependence is referral for opioid-assisted therapy with methadone, but emerging evidence suggests that buprenorphine also should be considered. Medically supervised tapered doses of opioids during pregnancy often result in relapse to former use. Abrupt discontinuation of opioids in an opioid-dependent pregnant woman can result in preterm labor, fetal distress, or fetal demise. During the intrapartum and postpartum period, special considerations are needed for women who are opioid dependent to ensure appropriate pain management, to prevent postpartum relapse and a risk of overdose, and to ensure adequate contraception to prevent unintended pregnancies. Patient stabilization with opioid-assisted therapy is compatible with breastfeeding. Neonatal abstinence syndrome is an expected and treatable condition that follows prenatal exposure to opioid agonists.
PP - United States
PY - 2012
SN - 1873-233X; 0029-7844
SP - 1070
EP - 1076
EP - 
T1 - ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy
T2 - Obstetrics and gynecology
TI - ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy
U1 - Opioids & Substance Use
U2 - 22525931
U3 - 10.1097/AOG.0b013e318256496e
VL - 119
VO - 1873-233X; 0029-7844
Y1 - 2012
ER -